NCT06816030View on ClinicalTrials.gov

A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 28, 2023

Primary Completion Date

August 5, 2023

Study Completion Date

August 5, 2023

Conditions
Healthy
Interventions
DRUG

MK-4482

Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day 1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours (Q12H) on Day 1 through Day 6 for11 doses.

Trial Locations (1)

100191

Peking University Third Hospital (Site 0001), Beijing

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY